These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 15264190)

  • 21. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
    Pepine CJ; Handberg EM; Cooper-DeHoff RM; Marks RG; Kowey P; Messerli FH; Mancia G; Cangiano JL; Garcia-Barreto D; Keltai M; Erdine S; Bristol HA; Kolb HR; Bakris GL; Cohen JD; Parmley WW;
    JAMA; 2003 Dec; 290(21):2805-16. PubMed ID: 14657064
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients.
    Griffith TF; Chua BS; Allen AS; Klassen PS; Reddan DN; Szczech LA
    Am J Kidney Dis; 2003 Dec; 42(6):1260-9. PubMed ID: 14655199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlates of subclinical left ventricular dysfunction in ESRD.
    Fathi R; Isbel N; Haluska B; Case C; Johnson DW; Marwick TH
    Am J Kidney Dis; 2003 May; 41(5):1016-25. PubMed ID: 12722036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ventricular hypertrophy and hypertension: prognostic elements and implications for management.
    Krauser DG; Devereux RB
    Herz; 2006 Jun; 31(4):305-16. PubMed ID: 16810470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Goals of antihypertensive therapy.
    McVeigh GE; Flack J; Grimm R
    Drugs; 1995 Feb; 49(2):161-75. PubMed ID: 7729325
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The cost effectiveness of ACE inhibitors as first-line antihypertensive therapy.
    Nordmann AJ; Krahn M; Logan AG; Naglie G; Detsky AS
    Pharmacoeconomics; 2003; 21(8):573-85. PubMed ID: 12751915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk-benefit ratio of angiotensin antagonists versus ACE inhibitors in end-stage renal disease.
    Sica DA; Gehr TW; Fernandez A
    Drug Saf; 2000 May; 22(5):350-60. PubMed ID: 10830252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ACE inhibitors captopril and enalapril induce regression of left ventricular hypertrophy in hypertensive patients with chronic renal failure.
    Dyadyk AI; Bagriy AE; Lebed IA; Yarovaya NF; Schukina EV; Taradin GG
    Nephrol Dial Transplant; 1997 May; 12(5):945-51. PubMed ID: 9175047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [How to choose and adequate antihypertensive drug depending on the type of the existing heart damage?].
    Alegría Ezquerra E; Martínez Monzonís A; Grau Sepúlveda A
    Rev Esp Cardiol; 1997; 50 Suppl 4():57-60. PubMed ID: 9411589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Management of hypertensive patients with cardiovascular damage].
    Tomiyama H; Takata Y; Yamashina A
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():612-6. PubMed ID: 15171444
    [No Abstract]   [Full Text] [Related]  

  • 31. Left ventricular hypertrophy and antihypertensive therapy.
    Graettinger WF; Weber MA
    Am Fam Physician; 1992 Aug; 46(2):483-91. PubMed ID: 1386180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
    Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypertension Management in Transition: From CKD to ESRD.
    Valika A; Peixoto AJ
    Adv Chronic Kidney Dis; 2016 Jul; 23(4):255-61. PubMed ID: 27324679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD)].
    Shibasaki Y; Nishiue T; Masaki H; Matsubara H; Iwasaka T
    Nihon Rinsho; 2002 Oct; 60(10):1992-8. PubMed ID: 12397697
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antihypertensive Medications in End-Stage Renal Disease.
    Denker MG; Cohen DL
    Semin Dial; 2015; 28(4):330-6. PubMed ID: 25877881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular complications in renal failure.
    Rostand SG; Brunzell JD; Cannon RO; Victor RG
    J Am Soc Nephrol; 1991 Dec; 2(6):1053-62. PubMed ID: 1777585
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Left ventricular hypertrophy in end-stage renal disease and its possible regression as a result of correction of anemia and arterial hypertension].
    Dzgoeva FU; Gatagonova TM; Kadzaeva ZK; Khamitsaeva OV; Kochisova ZKh; Dzutseva AT; Bazaeva BG
    Ter Arkh; 2011; 83(6):42-6. PubMed ID: 21786575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Use of antihypertensive drugs in France and relationship with cardiovascular disease. FLAHS 2009-2010 surveys].
    Girerd X; Laroche P; Hanon O; Pannier B; Postel-Vinay N; Mourad JJ
    Ann Cardiol Angeiol (Paris); 2012 Jun; 61(3):213-7. PubMed ID: 22695024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies.
    Zannad F; Kessler M; Lehert P; Grünfeld JP; Thuilliez C; Leizorovicz A; Lechat P
    Kidney Int; 2006 Oct; 70(7):1318-24. PubMed ID: 16871247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of antihypertensive treatment in chronic renal failure: to what extent and with which drugs do patients treated by nephrologists achieve the recommended blood pressure?
    Giverhaug T; Falck A; Eriksen BO
    J Hum Hypertens; 2004 Sep; 18(9):649-54. PubMed ID: 15002005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.